Sumary of Expert discusses expanding roster of options for dry eye disease:
- Back to Healio NEW ORLEANS — Recent years have brought several significant advances in dry eye disease treatment, Amy Lin, MD, said during Cornea Subspecialty Day at the American Academy of Ophthalmology meeting.
- New treatments for dry eye disease (DED) include novel mechanisms of action and delivery systems.
- Amy Lin Lin discussed FDA-approved DED treatments including Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%, Kala Pharmaceuticals), Tyrvaya (varenicline solution 0.03 mg, Oyster Point Pharma) and iTEAR100 (Olympic Ophthalmics).
- Eysuvis, which was approved in October 2020 for short-term DED, uses proprietary Ampplify mucus-penetrating technology to improve symptoms and signs of DED, Lin said, noting that she mainly uses Eysuvis for acute dry eye flares, but that it can also be used for induction therapy when initiating chronic topical anti-inflammatory treatment.
- “There are several novel existing and potential future treatments for dry eye disease,” Lin said.